Children and adolescents
Use of Feliben with other medications:
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
• Feliben should not be taken with monoamine oxidase inhibitors (certain medications for depression treatment) or if you have taken this type of medication in the last two weeks.
• Feliben may cause drowsiness, vomiting, dizziness, or make you breathe more slowly or weakly in some patients. These adverse effects may intensify if taken at the same time as other medications that can cause the same effects. These other medications include other powerful painkillers (opioids), some sleep medications, tranquilizers, anesthetics, antidepressants, and neuroléptics (medications for the treatment of certain psychological disorders).
• The concomitant use of Feliben and sedative medications such as benzodiazepines or related medications increases the risk of drowsiness, difficulty breathing (respiratory depression), coma, and may put your life at risk. Therefore, concomitant use should only be considered when other treatment options are not possible.
However, if your doctor prescribes Feliben along with sedative medications, your doctor should limit the dose and duration of concomitant treatment.
Please inform your doctor about all sedative medications you are taking and follow your doctor's recommended dose closely. It may be helpful to inform friends or family members to be aware of the signs and symptoms mentioned above. Contact your doctor when you experience these symptoms.
• If Feliben is used with other medications that block the degradation of buprenorphine, the patch's action may be intensified. These medications include, for example, certain antibiotics/antifungals (e.g., containing erythromycin or ketoconazole) or HIV medications (e.g., containing ritonavir).
• If Feliben is used with other medications that increase its degradation, the patch's action may be reduced. These medications include, for example, dexamethasone, certain epilepsy treatments (e.g., containing carbamazepine or phenytoin) or antituberculosos (e.g., containing rifampicin).
• Gabapentina or pregabalina used to treat epilepsy or pain due to nerve problems (neuropathic pain).
• Medications for depression treatment;
• Medications used to treat allergies and for vomiting or nausea during travel (antihistamines or antiemetics).
• Medications for the treatment of psychological disorders (antipsychotics or neuroléptics).
• Muscle relaxants
• Medications for Parkinson's disease treatment
Use of Feliben with food, drinks, and alcohol
You should avoid drinking alcohol while taking Feliben. Alcohol may increase certain effects of the transdermal patches, and you may not feel well. If you drink orange juice, it may intensify the effects of Feliben.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
There is not enough experience with the use of Feliben to date in pregnant women. Therefore, Feliben should not be used if you are pregnant.
Buprenorphine, the active ingredient contained in the patch, inhibits milk production and passes into breast milk. Therefore, Feliben should not be used during breastfeeding.
Driving and operating machinery
Feliben may make you feel dizzy, sleepy, or have blurred or double vision, and alter your reflexes in such a way that you may not react quickly or adequately in sudden or unexpected situations.
This applies especially:
If this happens to you, do not drive or operate machinery while taking Feliben.
This also applies to the end of treatment with Feliben. Do not drive or operate machinery. Do not do so for at least 24 hours after the patch has been removed.
In case of doubt, consult your doctor or pharmacist.
Feliben contains soy oil. If you are allergic to peanuts or soy, do not use this medication.
Use this medication exactly as your doctor has told you to. Consult with your doctor or pharmacist if you are unsure.
Before starting treatment and at regular intervals during treatment, your doctor will discuss with you what you can expect from the use of Feliben, when and for how long you should take it, when to contact your doctor, and when to stop taking it (see also "If you interrupt treatment with Feliben").
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Feliben is available in three doses:
Feliben 35 micrograms/hour transdermal patches, Feliben 52.5 micrograms/hour transdermal patches, and Feliben 70 micrograms/hour transdermal patches.
Your doctor has chosen this Feliben patch, as the most suitable for you. During treatment, your doctor may change the patch you use to a higher one if necessary. Use Feliben exactly as your doctor has told you to. If you have any doubts, consult your doctor or pharmacist.
The recommended dose is:
Adults
Apply Feliben (as detailed below) and change it after a maximum of 3 days. To help you remember the frequency of change, note it on the packaging. If your doctor has told you to take other painkillers in addition to the transdermal patch, follow your doctor's instructions strictly, otherwise you will not benefit fully from treatment with Feliben.
Use in children and adolescents
Feliben should not be used in people under 18 years of age because there is no experience with this age group so far.
Older adults
No dose adjustment is required in older adults.
Patients with renal impairment / patients on dialysis
No dose adjustment is required in patients with renal impairment and on dialysis.
Patients with liver impairment
In patients with liver impairment, the intensity and duration of Feliben's action may be affected. If you belong to this group of patients, your doctor will monitor you more closely.
Instructions for opening the child-resistant safety package:
Method of administration
Before applying the patch:
Applying the patch:
1.Each patch is sealed in a package. Do not open the package until the time of use of the patch.
2.Start by separating the protective film that covers the silver part.
3.Carefully remove the half of the film. Try not to touch the adhesive part of the patch.
4.Stick the patch to the area of skin you have chosen and remove the rest of the film.
5.Press the patch against your skin with the palm of your hand for 30-60 seconds. Make sure the entire patch is in contact with your skin, especially the edges.
6.Wash your hands after applying the transdermal patch. Do not use any cleaning products.
While wearing the patch:
You can wear the patch for a maximum of3days. If the patch has been applied correctly, the risk of it falling off is low. You can bathe, shower, or swim while wearing it. However, do not expose the patch to extreme heat (for example, sauna, infrared lamps, electric blankets, hot water bottle).
If the patch falls off before you need to change it, do not use the same patch again. Apply a new one immediately (see "Changing the patch").
Changing the patch:
Duration of treatment:
Your doctor will tell you the duration of your treatment with Feliben. Do not stop treatment prematurely, as the pain may return and you may feel unwell (see also "Effects when treatment with Feliben is interrupted").
If you think Feliben's action is too strong or too weak, tell your doctor or pharmacist.
If you use more Feliben patches than you should::
If this happens, there may be signs of buprenorphine overdose. An overdose can intensify the adverse effects of buprenorphine, such as drowsiness, nausea, and vomiting. Your pupils may be pinpointed, and your breathing may become slow and weak. You may experience a cardiovascular collapse.
As soon as you realize you have used more Feliben patches than you should, remove the excess patches and consult your doctor or pharmacist immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20.
If you forget to use Feliben:
If you forget an application, apply a new patch as soon as you remember. If you change the patch too late, the pain may return. In this case, consult your doctor.
Never apply double the number of transdermal patches to compensate for the one you forgot.
If you interrupt treatment with Feliben:
If you interrupt or stop treatment with Feliben too soon, the pain will return.
If you want to stop treatment due to unpleasant side effects, consult your doctor. Your doctor will tell you what you can do and if other medications can be administered.
Some people may experience effects after using potent analgesics for a long time and stopping them. The risk of experiencing effects after stopping Feliben is very low. However, if you feel agitated, anxious, nervous, or tremulous, if you are hyperactive, have difficulty sleeping, or experience digestive problems, consult your doctor.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Adverse reactions are classified as follows:
Very common: May affect more than 1 in 10 people | Common: May affect up to 1 in 10 people |
Uncommon: May affect up to 1 in 100 people | Rare: May affect up to 1 in 1,000 people |
Very rare: May affect up to 1 in 10,000 people | Frequency not known: Cannot be estimated from available data |
The following adverse effects have been reported:
Immune system disorders
Very rare: severe allergic reactions (see below)
Metabolic and nutritional disorders
Rare: loss of appetite
Mental disorders
Uncommon: confusion, sleep disorders, restlessness
Rare: illusions such as hallucinations, anxiety, and nightmares, decreased libido
Very rare: medication dependence, mood changes
Nervous system disorders
Common: dizziness, headache
Uncommon: sedation, ranging from drowsiness to numbness, difficulty concentrating, speech disorders, numbness, alteration of balance, paresthesia (numbness, sensation of heat or tingling in the skin)
Very rare: muscle contraction, alterations of taste
Eye disorders
Rare: vision disturbances, blurred vision, eyelid swelling
Very rare: constricted pupils (miosis)
Auditory disorders
Very rare: ear pain
Cardiovascular and circulatory disorders
Uncommon: circulatory disorders (such as hypotension or rarely, loss of consciousness due to low blood pressure)
Rare: hot flashes
Chest and lung disorders
Common: shortness of breath
Rare: difficulty breathing (respiratory depression)
Very rare: increased ventilation, hiccups
Digestive system disorders
Very common: nausea (feeling unwell)
Common: vomiting, constipation
Uncommon: dry mouth
Rare: acid reflux
Very rare: hiccups
Skin disorders (usually at the application site)
Very common: redness, itching
Common: skin rash (usually due to repeated use), sweating
Uncommon: rash
Rare: urticaria
Very rare: pustules, vesicles
Frequency not known: contact dermatitis (skin rash with inflammation, which may include a burning sensation), skin discoloration.
Urinary system disorders
Uncommon: urinary retention (less urine than normal), alterations of urination
Reproductive system disorders
Rare: decreased erection
General disorders
Common: edema (e.g., swelling of the legs), fatigue,
Uncommon: weakness
Rare: withdrawal symptoms (see below), reactions at the administration site
Very rare: chest pain
If you notice any of the above-mentioned side effects, inform your doctor as soon as possible.
In some cases, delayed adverse reactions with marked signs of inflammation occur. In these cases, discontinue Feliben treatment after discussing with your doctor.
If you experience swelling of the hands, feet, ankles, face, lips, mouth, or throat with difficulty swallowing and breathing, urticaria, dizziness, yellowing of the skin and eyes (also known as jaundice), remove the patch and immediately call your doctor or seek help at the nearest hospital.These symptoms may be attributed to a very severe and rare allergic reaction.
Some people may experience withdrawal symptoms when they have used potent painkillers for a prolonged treatment and then stop using them. Feliben has a low risk of dependence, and it is unlikely that withdrawal symptoms will occur after treatment with Feliben. However, if you feel agitated, anxious, nervous, are very active, have difficulty breathing, or experience gastrointestinal disorders, consult your doctor.
Reporting of adverse effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is an adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.Do not use this medication after the expiration date that appears on the packaging and on the overwrap after CAD. The expiration date is the last day of the month indicated.
Storage Conditions:
Do not store above25ºC.
Do not freeze.
Store this medication in a safe and protected place, where other people cannot access it. It may cause severe harm and be fatal to individuals who take it accidentally or intentionally when not prescribed.
Medications should not be disposed of through drains or in the trash. Deposit the packaging and unused medications at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Feliben 35 micrograms/hour transdermal patches:
The active ingredient is: Buprenorphin.
Feliben 35 micrograms/hour transdermal patch: Each transdermal patch contains 20 mg of buprenorphin and releases 35 micrograms per hour of buprenorphin. The contact area of the transdermal patch with the active ingredient is 25 cm2
The other components are:
Adhesive matrix (with buprenorphin):
styrene-butadiene-styrene (SBS) and styrene-butadiene copolymer group, colophony resins, antioxidants (2,4-bis (1,1-dimethylethyl)phenyl phosphite (3:1), Tris (2,4-di-tert-butylphenyl) phosphite), aloe vera leaf extract oil (also containing refined soybean oil and alpha-tocopherol acetate).
Separating layer of pigmented polyethylene, thermoplastic resin, and aluminum vapor-coated polyester, blue printing ink.
Release protection layer (to remove before applying): polyester layer, one side siliconized.
Appearance ofFelibenand contents of the package:
The patches are brown, rectangular with four edges and rounded corners, marked with Buprenorphin 35 µg/h.
Each patch is packaged in an individually sealed envelope.
Felibenis available in individually sealed envelopes in packages with 2, 3, 4, 5, 8, 10, 12, 16, 18, 20, 24, 25, and 30 transdermal patches.
Only some package sizes may be marketed.
The following concentrations are available:
Feliben 35 micrograms/hour
Feliben 52.5 micrograms/hour
Feliben 70 micrograms/hour
Marketing authorization holder and responsible manufacturer:
Marketing authorization holder:
Laboratorios Gebro Pharma, S.A.
Avda. Tibidabo, 29 – 08022 Barcelona (Spain)
Responsible manufacturer:
Luye Pharma AG
Am Windfeld, 35
D-83714 Miesbach (Germany)
or
MERCKLE GMBH
Ludwig-Merckle-Street, 3
D-89143 Blaubeuren, Germany
or
ACTAVIS GROUP PTC EHF
Reykjavikurvegi, 76-78
IS-220 Hafnarfjordur, Iceland
This medicine is authorized in the member states of the European Economic Area with the following names:
Germany:Acinorphin 35 Mikrogramm/Stunde Transdermal Pflaster
Acinorphin 52,5 Mikrogramm/Stunde Transdermal Pflaster
Acinorphin 70 Mikrogramm/Stunde Transdermal Pflaster
United Kingdom:Hapoctasin 35 micrograms/h, transdermal patches
Hapoctasin 52.5 micrograms/h, transdermal patches
Hapoctasin 70 micrograms/h, transdermal patches
Last review date of thisleaflet:November 2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.